Metabolomic Analysis of Exhaled Breath Condensates in Patients With COPD and Bronchiectasis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01410422
First received: August 4, 2011
Last updated: NA
Last verified: May 2011
History: No changes posted
  Purpose

Metabolomics is a large-scale approach to monitoring the compounds involved in cellular processes. It may reflect changes in biological function. Collection of exhaled breath is a newly developed, noninvasive method that may allow clinicians and researchers to assess biochemical profiles in the airway. This study is conducted for the metabolomic analysis of the exhaled gas in patients with Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis.


Condition
COPD
Bronchiectasis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Exhaled Breath Analysis in Patients With COPD and Bronchiectasis

Further study details as provided by National Taiwan University Hospital:

Biospecimen Retention:   Samples Without DNA

Breath condensate, blood, urine


Estimated Enrollment: 250
Study Start Date: May 2011
Estimated Study Completion Date: April 2014
Groups/Cohorts
COPD
COPD
Bronchiectasis
Bronchiectasis

Detailed Description:

Metabolomics is a large-scale approach to monitoring as many as possible of the compounds involved in cellular processes in a single assay to derive metabolic profiles. Compared with genomics or proteomics, metabolomics reflects changes in phenotype and therefore function. Collection of exhaled breath condensate (EBC) is a newly developed, noninvasive method that may allow clinicians and researchers to assess biochemical profiles in the alveolar lining fluid. The aims of this study are: (1)Collecting and metabolomic profiling of the EBCs from patients with COPD/bronchiectasis; (2) Comparing the profiles of these patients obtained during stable and acute exacerbation periods; (3) Comparing the profiles of these patients with and without Pseudomonas colonization/infection; (4) Correlation of EBC metabolomic profiles with clinical phenotypes, severity and outcomes of these patients.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with COPD and bronchiectasis

Criteria

Inclusion Criteria:

  • patients with COPD or bronchiectasis

Exclusion Criteria:

  • not willing to sign ICF
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01410422

Contacts
Contact: Ping-Hung Kuo 886-972651067 Kph712@ntuh.gov.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Ping-Hung Kuo, M.D.    886-972651067      
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Ping-Hung Kuo, M.D. National Taiwan University Hospital
  More Information

No publications provided

Responsible Party: Ping-Hung Kuo, MD., National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01410422     History of Changes
Other Study ID Numbers: 201103010RC
Study First Received: August 4, 2011
Last Updated: August 4, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
COPD
Bronchiectasis
Metabolomics

Additional relevant MeSH terms:
Bronchiectasis
Pulmonary Disease, Chronic Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases

ClinicalTrials.gov processed this record on April 17, 2014